Hidemichi Takai, Yoichi Sunagawa, Masafumi Funamoto, Kana Shimizu, Satoshi Shimizu, Yasufumi Katanasaka, Yusuke Miyazaki, Atsusi Imaizumi, Tadashi Hashimoto, Hiromichi Wada, Koji Hasegawa, Tatsuya Morimoto
{"title":"一种新的姜黄素制剂ASD-Cur抑制大鼠心肌梗死后收缩功能障碍的发展。","authors":"Hidemichi Takai, Yoichi Sunagawa, Masafumi Funamoto, Kana Shimizu, Satoshi Shimizu, Yasufumi Katanasaka, Yusuke Miyazaki, Atsusi Imaizumi, Tadashi Hashimoto, Hiromichi Wada, Koji Hasegawa, Tatsuya Morimoto","doi":"10.15420/ecr.2021.16.PO13","DOIUrl":null,"url":null,"abstract":"© RADCLIFFE CARDIOLOGY 2021 Access at: www.ECRjournal.com Objective: It has previously been reported that curcumin prevents the development of heart failure in animal models, demonstrating that the compound is a potential treatment for the disease in humans. Although curcumin is known to be safe, its therapeutic efficiency is limited due to its low bioavailability. To overcome this problem, we developed ASD-Cur, an amorphous formulation of curcumin. In this study, we investigated the effect of ASD-Cur and compared it with Theracurmin®, a colloidal submicron dispersion of curcumin.","PeriodicalId":93994,"journal":{"name":"European cardiology","volume":" ","pages":"e69"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/30/eb/ecr-16-e69.PMC8785084.pdf","citationCount":"0","resultStr":"{\"title\":\"A Novel Curcumin Formulation, ASD-Cur, Suppressed the Development of Systolic Dysfunction After Myocardial Infarction in Rats.\",\"authors\":\"Hidemichi Takai, Yoichi Sunagawa, Masafumi Funamoto, Kana Shimizu, Satoshi Shimizu, Yasufumi Katanasaka, Yusuke Miyazaki, Atsusi Imaizumi, Tadashi Hashimoto, Hiromichi Wada, Koji Hasegawa, Tatsuya Morimoto\",\"doi\":\"10.15420/ecr.2021.16.PO13\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"© RADCLIFFE CARDIOLOGY 2021 Access at: www.ECRjournal.com Objective: It has previously been reported that curcumin prevents the development of heart failure in animal models, demonstrating that the compound is a potential treatment for the disease in humans. Although curcumin is known to be safe, its therapeutic efficiency is limited due to its low bioavailability. To overcome this problem, we developed ASD-Cur, an amorphous formulation of curcumin. In this study, we investigated the effect of ASD-Cur and compared it with Theracurmin®, a colloidal submicron dispersion of curcumin.\",\"PeriodicalId\":93994,\"journal\":{\"name\":\"European cardiology\",\"volume\":\" \",\"pages\":\"e69\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-12-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/30/eb/ecr-16-e69.PMC8785084.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European cardiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15420/ecr.2021.16.PO13\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/2/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15420/ecr.2021.16.PO13","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/2/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
